Quantum News
Sign InSign Up
Back to News
research

Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Gossamer Bio revealed topline results from its Phase 3 PROSERA study evaluating seralutinib for pulmonary arterial hypertension (PAH) on February 23, 2026. The trial assessed seralutinib’s efficacy and safety in PAH patients, with executives including CEO Faheem Hasnain and Chief Medical Officer Richard Aranda presenting key findings during an earnings call. While specific outcomes weren’t detailed in the transcript, the company emphasized the study’s significance for addressing unmet needs in PAH, a progressive and life-threatening condition. Analysts from firms like Leerink Partners, Piper Sandler, and Goldman Sachs participated, signaling strong industry interest in the drug’s potential market impact. Gossamer Bio cautioned that forward-looking statements carry risks, noting actual results may differ from projections due to clinical and regulatory uncertainties.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (28).png
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts158.56K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension February 23, 2026 8:30 AM EST Company Participants Bryan Giraudo - COO & CFOFaheem Hasnain - Co-Founder, CEO, President & ChairmanRichard Aranda - Chief Medical OfficerRobert Roscigno - Senior Vice President of Clinical Development of Pulmonary Vascular DiseaseCaryn Peterson - Executive Vice President of Regulatory Affairs Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research DivisionYasmeen Rahimi - Piper Sandler & Co., Research DivisionKyuwon Choi - Goldman Sachs Group, Inc., Research DivisionAndreas Argyrides - Oppenheimer & Co. Inc., Research DivisionOlivia Brayer - Cantor Fitzgerald & Co., Research DivisionPatrick Trucchio - H.C. Wainwright & Co, LLC, Research DivisionEliana Merle - Barclays Bank PLC, Research DivisionLaura Chico - Wedbush Securities Inc., Research DivisionVamil Divan - Guggenheim Securities, LLC, Research Division Presentation Operator Thank you for standing by. My name is Dina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Gossamer Bio Inc. PROSERA Phase 3 Topline Results Call. [Operator Instructions] It is now my pleasure to turn today's program over to Bryan Giraudo. Please go ahead. Bryan GiraudoCOO & CFO Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release announcing top line results from PROSERA, our Phase III study of seralutinib pulmonary arterial hypertension. The press release is available on the Investors section of our website. Joining me today are Gossamer executives, Faheem Hasnain, Dr. Richard Aranda, Bob Smith, Dr. Rob Roscigno and Caryn Peterson. Before we begin, I'd like to remind you that we'll be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. For a

Read Original

Tags

quantum-finance

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.